Home » Stocks » Provention Bio

Provention Bio, Inc. (PRVB)

Stock Price: $12.84 USD 0.78 (6.47%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 722.64M
Revenue (ttm) n/a
Net Income (ttm) -55.01M
Shares Out 56.28M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $12.84
Previous Close $12.06
Change ($) 0.78
Change (%) 6.47%
Day's Open 12.04
Day's Range 12.04 - 12.93
Day's Volume 341,362
52-Week Range 4.72 - 18.50

More Stats

Market Cap 722.64M
Enterprise Value 550.48M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.28M
Float 45.37M
EPS (basic) -1.16
EPS (diluted) -1.19
FCF / Share -0.93
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.57M
Short Ratio 6.83
Short % of Float 10.08%
Beta 3.53
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.59
Revenue n/a
Operating Income -56.52M
Net Income -55.01M
Free Cash Flow -45.71M
Net Cash 172.16M
Net Cash / Share 3.06
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.38%
ROE -54.69%
ROIC -243.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(118.07% upside)
Current: $12.84
Target: 28.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-44.37-26.81-9.14
Net Income-43.29-26.48-9.13
Shares Outstanding40.7522.449.37
Earnings Per Share-1.06-1.19-1.01
Operating Cash Flow-36.07-22.64-4.88
Free Cash Flow-36.07-22.64-4.88
Cash & Equivalents85.3758.5421.83
Net Cash / Debt85.3758.5421.83
Book Value82.1659.66-6.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Provention Bio, Inc.
Country United States
Employees 19
CEO Ashleigh W. Palmer

Stock Information

Ticker Symbol PRVB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRVB


Provention Bio, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.